Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)

Key facts

Sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Principal Investigator

Dolores Caballero, MD

Hospital Clínico Universitario de Salamanca

Intervention

Ibritumomab Tiuxetan (Zevalin)(drug)

Enrollment

20 enrolled

Eligibility

18-65 years · All sexes

Timeline

2007 – 2013

Study locations (14)

• H. Santa Creu i Sant Pau., Barcelona, Barcelona., Spain
• H. U. Marqués de Valdecilla., Santander, Cantabria, Spain
• H.U. 12 de Octubre, Madrid, Madrid, Spain
• H.U. Gregorio Marañón, Madrid, Madrid, Spain
• H.U. La Princesa, Madrid, Madrid, Spain
• H.U. Ramón y Cajal., Madrid, Madrid, Spain
• H. Morales Meseguer., Murcia, Murcia, Spain
• H. Virgen de la Arrixaca, Murcia, Murcia, Spain
• Clinica Universitaria de Navarra, Pamplona, Navarre, Spain
• H. Central de Asturias, Oviedo, Oviedo, Spain
• H. Clinico de Salamanca, Salamanca, Salamanca, Spain
• H. Clínico Valencia, Valencia, Valencia, Spain
• H. La Fe, Valencia, Valencia, Spain
• H.U. Miguel Servet, Zaragoza, Zaragoza., Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Aggressive B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNCT07474051
  Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
  AvenCell Therapeutics, Inc.
• RECRUITINGEARLY PHASE1NCT07344818
  An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
  Peking University People's Hospital
• RECRUITINGPHASE2NCT07097363
  Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
  University of Washington
• RECRUITINGPHASE2NCT06649812
  Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE2, PHASE3NCT07168980
  Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
  Children's Cancer Group, China
• RECRUITINGPHASE2NCT06996132
  Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE2NCT06834373
  Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
  Mayo Clinic
• RECRUITINGPHASE1, PHASE2NCT06536049
  Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Yazeed Sawalha

See all trials for Aggressive B-cell non-Hodgkin lymphoma →